Strategic Partners A/S — Director's Dealing 2017

Nov 21, 2017

Company announcement Orphazyme A/S No. 13/2017 Ole Maaløes Vej 3

DK-2200 Copenhagen N

www.orphazyme.com Company Registration No. 32266355

21 November 2017

Reporting of transactions made by persons discharging managerial responsibilities in Orphazyme A/S

Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 ("Orphazyme"), hereby notifies receipt of information regarding the following grants under Orphazyme's long-term incentive programme as further described in company announcement 8/2017:

1	Details of the Reporting Person / Closely Associated Person
	a) Name	Anders Hinsby
2	Reason for the notification
	a) Position/status	Chief Executive Officer
	b) Initial notification/Amendment	Initial notification
3	Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
	a) Name	Orphazyme A/S
	b) LEI code	54930025OZD2GGSQ7L42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
	a) Description of the financial instrument, type of instrument and identification code	Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917
	b) Nature of the transaction	Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme

	c) Price(s) and volume(s)
		Price (s) 0 0	Volume(s) 5,000 (Matching shares) 30,000 (Performance shares assuming full vesting)
	d) Aggregated information - Aggregated volume - Price
	e) Date of the transaction	2017-11-21 17:00 UTC+1
f)	Place of the transaction	Outside a trading venue

1	Details of the Reporting Person / Closely Associated Person
	a) Name	Anders Vadsholt
2	Reason for the notification
	a) Position/status	Chief Financial Officer
	b) Initial notification/Amendment	Initial notification
3	Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
	a) Name	Orphazyme A/S
	b) LEI code	54930025OZD2GGSQ7L42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
	a) Description of the financial instrument, type of instrument and identification code	performance shares in Orphazyme A/S ISIN DK0060910917	Rights to acquire or subscribe for matching shares and
	b) Nature of the transaction	programme	Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive
	c) Price(s) and volume(s)	Price (s) 0 0	Volume(s) 4,000 (Matching shares) 16,000 (Performance shares assuming full vesting)

	d) Aggregated information - Aggregated volume
	- Price
	e) Date of the transaction	2017-11-21 17:00 UTC+1
f)	Place of the transaction	Outside a trading venue

1	Details of the Reporting Person / Closely Associated Person
	a) Name	Thomas Kirkegaard Jensen
2	Reason for the notification
	a) Position/status	Chief Scientific Officer
	b) Initial notification/Amendment	Initial notification
3	Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
	a) Name	Orphazyme A/S
	b) LEI code	54930025OZD2GGSQ7L42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
	a) Description of the financial instrument, type of instrument and identification code	Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917
	b) Nature of the transaction	Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme
	c) Price(s) and volume(s)	Price (s) Volume(s) 0 4,000 (Matching shares) 0 16,000 (Performance shares assuming full vesting)
	d) Aggregated information - Aggregated volume - Price
	e) Date of the transaction	2017-11-21 17:00 UTC+1
f)	Place of the transaction	Outside a trading venue

1	Details of the Reporting Person / Closely Associated Person
	a) Name	Thomas Blaettler
2	Reason for the notification
	a) Position/status	Chief Medical Officer
	b) Initial notification/Amendment	Initial notification
3	Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
	a) Name	Orphazyme A/S
	b) LEI code	54930025OZD2GGSQ7L42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
	a) Description of the financial instrument, type of instrument and identification code	Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917
	b) Nature of the transaction	Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme
	c) Price(s) and volume(s)	Price (s) Volume(s) 0 1,875 (Matching shares) 0 7,500 (Performance shares assuming full vesting)
	d) Aggregated information - Aggregated volume - Price
	e) Date of the transaction	2017-11-21 17:00 UTC+1
f)	Place of the transaction	Outside a trading venue

For additional information, please contact

Orphazyme

Anders Vadsholt, CFO +45 28 98 90 55